Advertisement
UK markets closed
  • FTSE 100

    8,213.49
    +41.34 (+0.51%)
     
  • FTSE 250

    20,164.54
    +112.24 (+0.56%)
     
  • AIM

    771.53
    +3.42 (+0.45%)
     
  • GBP/EUR

    1.1666
    +0.0014 (+0.12%)
     
  • GBP/USD

    1.2557
    +0.0010 (+0.08%)
     
  • Bitcoin GBP

    51,201.49
    +708.20 (+1.40%)
     
  • CMC Crypto 200

    1,371.94
    +59.31 (+4.52%)
     
  • S&P 500

    5,127.79
    +63.59 (+1.26%)
     
  • DOW

    38,675.68
    +449.98 (+1.18%)
     
  • CRUDE OIL

    78.72
    +0.61 (+0.78%)
     
  • GOLD FUTURES

    2,322.60
    +14.00 (+0.61%)
     
  • NIKKEI 225

    38,236.07
    -38.03 (-0.10%)
     
  • HANG SENG

    18,569.99
    +94.07 (+0.51%)
     
  • DAX

    18,001.60
    +105.10 (+0.59%)
     
  • CAC 40

    7,957.57
    +42.92 (+0.54%)
     

Sanofi poaches former PSA finance boss Chasseloup de Chatillon

FILE PHOTO: French multinational pharmaceutical company SANOFI logo is seen at the headquarters in Paris, France, March 8, 2016. REUTERS/Philippe Wojazer/File Photo (Reuters)

PARIS (Reuters) - French drugmaker Sanofi <SASY.PA> announced it had hired Jean-Baptiste Chasseloup de Chatillon, the former chief financial officer at carmaker and Peugeot-manufacturer PSA <PEUP.PA> who had helped oversee a revival in PSA's fortunes.

Sanofi said Chasseloup de Chatillon would become its executive vice-president and chief financial officer, with his position taking effect on October 1, replacing Jerome Contamine who will be retiring.

"Jean-Baptiste is an experienced CFO who has been part of the impressive turnaround of PSA Group," said Sanofi chief executive Olivier Brandicourt in a statement.

PSA had posted a series of record earnings results over the last two years, having rebounded from a 2012 brush with bankruptcy, and Chasseloup de Chatillon had been a member of Peugeot's managing board since 2012.

ADVERTISEMENT

Chasseloup de Chatillon will arrive at Sanofi at a time of blockbuster deals within the global healthcare industry.

Sanofi has already struck two major takeover deals this year, buying haemophilia specialist Bioverativ for $11.6 billion and acquiring Ablynx, which is developing a prized experimental drug for a rare blood disorder, for 3.9 billion euros (3.40 billion pounds).

The transactions marked a return to successful deal-making for Sanofi after failures to land major takeovers since 2011, when it bought U.S biotech company Genzyme for around $20 billion, although some investors have questioned the costs.

(Reporting by Sudip Kar-Gupta and Gilles Guillaume; Editing by Bate Felix)